Strongbridge Biopharma plc Company Profile (NASDAQ:SBBP)

About Strongbridge Biopharma plc (NASDAQ:SBBP)

Strongbridge Biopharma plc logoStrongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SBBP
  • CUSIP: N/A
  • Web: www.strongbridgebio.com
Capitalization:
  • Market Cap: $166.07 million
  • Outstanding Shares: 35,335,000
Average Prices:
  • 50 Day Moving Avg: $4.37
  • 200 Day Moving Avg: $3.57
  • 52 Week Range: $2.00 - $6.24
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.70
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.09 per share
  • Price / Book: 4.31
Profitability:
  • EBIDTA: ($34,900,000.00)
  • Return on Equity: -50.52%
  • Return on Assets: -47.00%
Debt:
  • Current Ratio: 6.08%
  • Quick Ratio: 6.08%
Misc:
  • Average Volume: 52,642 shs.
  • Beta: 2.75
  • Short Ratio: 3.37
 

Frequently Asked Questions for Strongbridge Biopharma plc (NASDAQ:SBBP)

What is Strongbridge Biopharma plc's stock symbol?

Strongbridge Biopharma plc trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma plc's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its earnings results on Tuesday, May, 16th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.49) by $0.16. View Strongbridge Biopharma plc's Earnings History.

Where is Strongbridge Biopharma plc's stock going? Where will Strongbridge Biopharma plc's stock price be in 2017?

2 brokerages have issued twelve-month target prices for Strongbridge Biopharma plc's shares. Their predictions range from $10.00 to $18.00. On average, they expect Strongbridge Biopharma plc's stock price to reach $14.00 in the next year. View Analyst Ratings for Strongbridge Biopharma plc.

Who are some of Strongbridge Biopharma plc's key competitors?

Who owns Strongbridge Biopharma plc stock?

Strongbridge Biopharma plc's stock is owned by a variety of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (11.72%), Broadfin Capital LLC (8.44%), Boxer Capital LLC (2.66%), Tredje AP fonden (2.57%) and Granite Point Capital Management L.P. (1.68%). View Institutional Ownership Trends for Strongbridge Biopharma plc.

Who sold Strongbridge Biopharma plc stock? Who is selling Strongbridge Biopharma plc stock?

Strongbridge Biopharma plc's stock was sold by a variety of institutional investors in the last quarter, including Granite Point Capital Management L.P.. View Insider Buying and Selling for Strongbridge Biopharma plc.

Who bought Strongbridge Biopharma plc stock? Who is buying Strongbridge Biopharma plc stock?

Strongbridge Biopharma plc's stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC. View Insider Buying and Selling for Strongbridge Biopharma plc.

How do I buy Strongbridge Biopharma plc stock?

Shares of Strongbridge Biopharma plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Strongbridge Biopharma plc stock cost?

One share of Strongbridge Biopharma plc stock can currently be purchased for approximately $4.70.

Analyst Ratings

Consensus Ratings for Strongbridge Biopharma plc (NASDAQ:SBBP) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.00 (197.87% upside)

Analysts' Ratings History for Strongbridge Biopharma plc (NASDAQ:SBBP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/17/2017HC WainwrightReiterated RatingBuyLowView Rating Details
12/28/2016JMP SecuritiesReiterated RatingOutperform$10.00N/AView Rating Details
2/3/2016Roth CapitalInitiated CoverageBuy$12.00N/AView Rating Details
12/10/2015Janney Montgomery ScottInitiated CoverageBuy$19.00N/AView Rating Details
12/7/2015Stifel NicolausReiterated RatingBuyN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Strongbridge Biopharma plc (NASDAQ:SBBP)
Earnings by Quarter for Strongbridge Biopharma plc (NASDAQ:SBBP)
Earnings History by Quarter for Strongbridge Biopharma plc (NASDAQ:SBBP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/20173/31/2017($0.49)($0.33)ViewN/AView Earnings Details
5/17/2016Q1($0.63)($0.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Strongbridge Biopharma plc (NASDAQ:SBBP)
Current Year EPS Consensus Estimate: $-2.06 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS

Dividends

Dividend History for Strongbridge Biopharma plc (NASDAQ:SBBP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Strongbridge Biopharma plc (NASDAQ:SBBP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Strongbridge Biopharma plc (NASDAQ:SBBP)
Latest Headlines for Strongbridge Biopharma plc (NASDAQ:SBBP)
Source:
DateHeadline
feeds.benzinga.com logoStrongbridge Biopharma plc to Present at the Jefferies 2017 Global Healthcare Conference
feeds.benzinga.com - May 25 at 7:55 AM
americanbankingnews.com logoZacks Investment Research Lowers Strongbridge Biopharma plc (SBBP) to Sell
www.americanbankingnews.com - May 18 at 7:10 PM
americanbankingnews.com logoStrongbridge Biopharma plc's (SBBP) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - May 18 at 7:54 AM
americanbankingnews.com logoStrongbridge Biopharma plc (SBBP) Posts Quarterly Earnings Results, Beats Estimates By $0.16 EPS
www.americanbankingnews.com - May 17 at 10:03 AM
americanbankingnews.com logo-$0.47 Earnings Per Share Expected for Strongbridge Biopharma plc (SBBP) This Quarter
www.americanbankingnews.com - May 5 at 4:19 PM
americanbankingnews.com logoStrongbridge Biopharma plc (SBBP) Earns Media Impact Score of 0.31
www.americanbankingnews.com - May 4 at 2:10 PM
americanbankingnews.com logoStrongbridge Biopharma plc (SBBP) Receives Daily News Impact Score of 0.31
www.americanbankingnews.com - April 28 at 6:50 PM
americanbankingnews.com logoStrongbridge Biopharma plc (SBBP) Earns Media Sentiment Rating of 0.09
www.americanbankingnews.com - April 15 at 4:25 PM
americanbankingnews.com logoZacks: Analysts Anticipate Strongbridge Biopharma plc (SBBP) to Post -$0.47 Earnings Per Share
www.americanbankingnews.com - April 14 at 4:30 PM
americanbankingnews.com logoStrongbridge Biopharma plc (SBBP) Sees Significant Growth in Short Interest
www.americanbankingnews.com - April 11 at 7:15 AM
americanbankingnews.com logoHC Wainwright Reaffirms "Buy" Rating for Strongbridge Biopharma plc (SBBP)
www.americanbankingnews.com - April 5 at 9:01 AM
americanbankingnews.com logoStrongbridge Biopharma plc (SBBP) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 4 at 8:18 AM
americanbankingnews.com logoStrongbridge Biopharma plc (SBBP) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 29 at 11:30 PM
finance.yahoo.com logoStrongbridge Biopharma plc Provides Corporate Update and Reports Full-Year 2016 Financial Results
finance.yahoo.com - March 27 at 9:18 AM
finance.yahoo.com logoStrongbridge Biopharma plc Announces New Employment Inducement Awards
finance.yahoo.com - March 17 at 7:47 PM
finance.yahoo.com logoStrongbridge Biopharma plc to Present at the 27th Annual Oppenheimer Healthcare Conference and the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 14 at 9:40 AM
americanbankingnews.com logoStrongbridge Biopharma plc (SBBP) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 13 at 2:48 PM
finance.yahoo.com logoCan The Uptrend Continue for Strongbridge Biopharma (SBBP)?
finance.yahoo.com - March 9 at 8:05 AM
finance.yahoo.com logoStrongbridge Biopharma plc Announces Annual General Meeting of Shareholders
finance.yahoo.com - March 7 at 9:19 AM
finance.yahoo.com logoStrongbridge Biopharma plc to Present at the 37th Annual Cowen and Company Healthcare Conference and the 29th Annual ROTH Conference
finance.yahoo.com - March 7 at 9:19 AM
finance.yahoo.com logoStrongbridge Biopharma plc to Participate in the Canaccord Genuity Rare Disease and BioPharma One-on-One Day
finance.yahoo.com - February 3 at 3:38 AM
finance.yahoo.com logoStrongbridge Biopharma plc Expands Commercial Capabilities with Two Rare Disease Executive Hires
finance.yahoo.com - January 9 at 9:08 AM
publicnow.com logoStrongbridge Biopharma plc Announces Closing of $35 Million Equity Financing and $40 Million Credit Facility
us.rd.yahoo.com - December 29 at 7:38 PM
us.rd.yahoo.com logo8:01 am Strongbridge Biopharma (thinly traded) enters into a securities purchase agreement for a placement of 14 mln of its ordinary shares priced at $2.50/share & warrants to purchase 7 mln shares for gross proceeds of $35 mln
us.rd.yahoo.com - December 23 at 7:49 PM
marketwatch.com logoStonebridge Biopharma raises $35 million by selling shares at a deep discount
www.marketwatch.com - December 23 at 7:49 PM
bizjournals.com logo$35M infusion: Bucks County biopharm firm reaches funding deal
www.bizjournals.com - December 23 at 7:49 PM
finance.yahoo.com logoStrongbridge Biopharma plc Announces Promotion of Fredric Cohen, M.D., to Chief Medical Officer
finance.yahoo.com - November 29 at 3:14 PM
finance.yahoo.com logoStrongbridge Biopharma (SBBP) Jumps: Stock Moves Up 5.5%
finance.yahoo.com - August 11 at 10:33 AM
finance.yahoo.com logoCoverage initiated on Strongbridge Biopharma by H.C. Wainwright
finance.yahoo.com - April 25 at 7:09 AM
thestreet.com logoStrongbridge Biopharma Plc Announces Presentation Of COR-003 Data At The Endocrine Society's 2016 Annual Conference
www.thestreet.com - April 4 at 10:23 AM
finance.yahoo.com logoSTRONGBRIDGE BIOPHARMA PLC Financials
finance.yahoo.com - March 30 at 1:04 PM
bizjournals.com logoBucks biopharm firm returns one drug candidate, stops development of another
www.bizjournals.com - March 7 at 10:55 AM
finance.yahoo.com logo7:33 am Strongbridge Biopharma provides update on corporate progress; co initiates the return of COR-004 to Antisense Therapeutics and will not invest further in the development of BP-2002
finance.yahoo.com - March 7 at 7:33 AM
finance.yahoo.com logoStrongbridge Biopharma plc Announces Presentations at Two Upcoming Investor Conferences
finance.yahoo.com - February 25 at 7:30 AM
finance.yahoo.com logoStrongbridge Biopharma Announces Annual General Meeting of Shareholders
finance.yahoo.com - February 18 at 4:05 PM
finance.yahoo.com logoStrongbridge Biopharma plc Announces Participation at SunTrust Robinson Humphrey’s 2016 Orphan Drug Day
finance.yahoo.com - February 18 at 7:30 AM
finance.yahoo.com logoMast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors
finance.yahoo.com - November 2 at 8:00 AM

Social

Chart

Strongbridge Biopharma plc (SBBP) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff